The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Abstract

Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.

Keywords

SpironolactoneMedicineHeart failureDigoxinInternal medicineRelative riskPlaceboEjection fractionCardiologyConfidence intervalSudden death

MeSH Terms

AgedAngiotensin-Converting Enzyme InhibitorsCause of DeathDiureticsDouble-Blind MethodDrug TherapyCombinationFemaleGynecomastiaHeart DiseasesHeart FailureHospitalizationHumansHyperkalemiaMaleMiddle AgedMineralocorticoid Receptor AntagonistsRiskSpironolactoneSurvival Analysis

Affiliated Institutions

Related Publications

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

Salim Yusuf , Peter Sleight , Janice Pogue +3 more

Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or ...

2000 New England Journal of Medicine 8597 citations

Pathophysiology of Valvular Aortic Stenois in the Elderly

Melvin D. Cheitlin

Aortic stenosis in the elderly is related to calcification of either a bicuspid valve or a morphologically normal tricuspid valve. There is increasing evidence that factors rela...

2003 The American Journal of Geriatric Car... 13 citations

Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction

Vera Bittner

<h3>Objective.</h3> —To study the potential usefulness of the 6-minute walk test, a self-paced submaximal exercise test, as a prognostic indicator in patients with left ventricu...

1993 JAMA 691 citations

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker , Javed Butler , Gerasimos Filippatos +38 more

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless...

2021 New England Journal of Medicine 4054 citations

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray , Scott D. Solomon , Silvio E. Inzucchi +35 more

BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through ...

2019 New England Journal of Medicine 6238 citations

Publication Info

Year: 1999
Type: article
Volume: 341
Issue: 10
Pages: 709-717
Citations: 8920
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

8920

OpenAlex

147

Influential

7351

CrossRef

Cite This

APA Style

                            
                                
                                    Bertram Pitt, 
                                
                                    Faı̈ez Zannad, 
                                
                                    Willem J. Remme
                                
                                et al.
                            
                            (1999). 
                            The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. 
                            New England Journal of Medicine
                            , 341
                            (10)
                            , 709-717.
                            https://doi.org/10.1056/nejm199909023411001
                        

Identifiers

DOI: 10.1056/nejm199909023411001
PMID: 10471456

Data Quality

Data completeness: 86%